APO Research
Talk to an analyst

APO RESEARCH · REPORT

IgA Nephropathy Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global IgA Nephropathy Drugs Industry Growth and Trends Forecast to 2032

29 December 202592 pages

Choose your research edition.

Industry ResearchIgA Nephropathy Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal IgA Nephropathy Drugs Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal IgA Nephropathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IgA Nephropathy Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal IgA Nephropathy Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global IgA Nephropathy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IgA Nephropathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IgA Nephropathy Drugs include Calliditas Therapeutics, Chinook Therapeutics, Omeros Corporation, Travere Therapeutics, Vera Therapeutics, Otsuka Pharmaceutical and Novartis International, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global IgA Nephropathy Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The IgA Nephropathy Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global IgA Nephropathy Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to IgA Nephropathy Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global IgA Nephropathy Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

IgA Nephropathy Drugs Market by Company

Calliditas Therapeutics

Chinook Therapeutics

Omeros Corporation

Travere Therapeutics

Vera Therapeutics

Otsuka Pharmaceutical

Novartis International

IgA Nephropathy Drugs Segment by Type

Phase I

Phase II

Phase III

IgA Nephropathy Drugs Segment by Application

Clinical Treatment

Drug Experiment

IgA Nephropathy Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IgA Nephropathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IgA Nephropathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IgA Nephropathy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IgA Nephropathy Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of IgA Nephropathy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Phase I Table 2. Major Company of Phase II Table 3. Major Company of Phase III Table 4. Global IgA Nephropathy Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global IgA Nephropathy Drugs Sales by Type (2021-2026) & (K Units) Table 6. Global IgA Nephropathy Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global IgA Nephropathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global IgA Nephropathy Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global IgA Nephropathy Drugs Price by Type (2021-2026) & (US$/Unit) Table 10. Global IgA Nephropathy Drugs Sales by Type (2027-2032) & (K Units) Table 11. Global IgA Nephropathy Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global IgA Nephropathy Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global IgA Nephropathy Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global IgA Nephropathy Drugs Price by Type (2027-2032) & (US$/Unit) Table 15. North America IgA Nephropathy Drugs Sales by Type (2021-2026) & (K Units) Table 16. North America IgA Nephropathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe IgA Nephropathy Drugs Sales by Type (2021-2026) & (K Units) Table 18. Europe IgA Nephropathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific IgA Nephropathy Drugs Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific IgA Nephropathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America IgA Nephropathy Drugs Sales by Type (2021-2026) & (K Units) Table 22. Latin America IgA Nephropathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa IgA Nephropathy Drugs Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa IgA Nephropathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. IgA Nephropathy Drugs Industry Trends Table 26. IgA Nephropathy Drugs Industry Drivers Table 27. IgA Nephropathy Drugs Industry Opportunities and Challenges Table 28. IgA Nephropathy Drugs Industry Restraints Table 29. Global IgA Nephropathy Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global IgA Nephropathy Drugs Revenue Market Share by Company (2021-2026) Table 31. Global IgA Nephropathy Drugs Sales by Company (2021-2026) & (K Units) Table 32. Global IgA Nephropathy Drugs Sales Share by Company (2021-2026) Table 33. Global IgA Nephropathy Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global IgA Nephropathy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global IgA Nephropathy Drugs Major Company Production Sites and Headquarters Table 36. Global IgA Nephropathy Drugs Company, Product Type & Application Table 37. Global IgA Nephropathy Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global IgA Nephropathy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global IgA Nephropathy Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global IgA Nephropathy Drugs Sales by Region (2021-2026) & (K Units) Table 42. Global IgA Nephropathy Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global IgA Nephropathy Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global IgA Nephropathy Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global IgA Nephropathy Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global IgA Nephropathy Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global IgA Nephropathy Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global IgA Nephropathy Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global IgA Nephropathy Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global IgA Nephropathy Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global IgA Nephropathy Drugs Sales by Application (2021-2026) & (K Units) Table 53. Global IgA Nephropathy Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global IgA Nephropathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global IgA Nephropathy Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global IgA Nephropathy Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global IgA Nephropathy Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global IgA Nephropathy Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global IgA Nephropathy Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global IgA Nephropathy Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global IgA Nephropathy Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. North America IgA Nephropathy Drugs Sales by Application (2021-2026) & (K Units) Table 63. North America IgA Nephropathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe IgA Nephropathy Drugs Sales by Application (2021-2026) & (K Units) Table 65. Europe IgA Nephropathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific IgA Nephropathy Drugs Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific IgA Nephropathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America IgA Nephropathy Drugs Sales by Application (2021-2026) & (K Units) Table 69. Latin America IgA Nephropathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa IgA Nephropathy Drugs Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa IgA Nephropathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Calliditas Therapeutics Company Information Table 73. Calliditas Therapeutics Business Overview Table 74. Calliditas Therapeutics IgA Nephropathy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Calliditas Therapeutics IgA Nephropathy Drugs Product Portfolio Table 76. Calliditas Therapeutics Recent Development Table 77. Chinook Therapeutics Company Information Table 78. Chinook Therapeutics Business Overview Table 79. Chinook Therapeutics IgA Nephropathy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Chinook Therapeutics IgA Nephropathy Drugs Product Portfolio Table 81. Chinook Therapeutics Recent Development Table 82. Omeros Corporation Company Information Table 83. Omeros Corporation Business Overview Table 84. Omeros Corporation IgA Nephropathy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Omeros Corporation IgA Nephropathy Drugs Product Portfolio Table 86. Omeros Corporation Recent Development Table 87. Travere Therapeutics Company Information Table 88. Travere Therapeutics Business Overview Table 89. Travere Therapeutics IgA Nephropathy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Travere Therapeutics IgA Nephropathy Drugs Product Portfolio Table 91. Travere Therapeutics Recent Development Table 92. Vera Therapeutics Company Information Table 93. Vera Therapeutics Business Overview Table 94. Vera Therapeutics IgA Nephropathy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Vera Therapeutics IgA Nephropathy Drugs Product Portfolio Table 96. Vera Therapeutics Recent Development Table 97. Otsuka Pharmaceutical Company Information Table 98. Otsuka Pharmaceutical Business Overview Table 99. Otsuka Pharmaceutical IgA Nephropathy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Otsuka Pharmaceutical IgA Nephropathy Drugs Product Portfolio Table 101. Otsuka Pharmaceutical Recent Development Table 102. Novartis International Company Information Table 103. Novartis International Business Overview Table 104. Novartis International IgA Nephropathy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Novartis International IgA Nephropathy Drugs Product Portfolio Table 106. Novartis International Recent Development Table 107. North America IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 108. North America IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 109. North America IgA Nephropathy Drugs Sales Market Share by Country (2021-2026) Table 110. North America IgA Nephropathy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 111. North America IgA Nephropathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 112. North America IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. North America IgA Nephropathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 114. North America IgA Nephropathy Drugs Market Share by Country (2021-2026) Table 115. North America IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. North America IgA Nephropathy Drugs Market Share Forecast by Country (2027-2032) Table 117. Europe IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 118. Europe IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 119. Europe IgA Nephropathy Drugs Sales Market Share by Country (2021-2026) Table 120. Europe IgA Nephropathy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 121. Europe IgA Nephropathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 122. Europe IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Europe IgA Nephropathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 124. Europe IgA Nephropathy Drugs Market Share by Country (2021-2026) Table 125. Europe IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Europe IgA Nephropathy Drugs Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 129. Asia-Pacific IgA Nephropathy Drugs Sales Market Share by Country (2021-2026) Table 130. Asia-Pacific IgA Nephropathy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 131. Asia-Pacific IgA Nephropathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific IgA Nephropathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 134. Asia-Pacific IgA Nephropathy Drugs Market Share by Country (2021-2026) Table 135. Asia-Pacific IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Asia-Pacific IgA Nephropathy Drugs Market Share Forecast by Country (2027-2032) Table 137. Latin America IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Latin America IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 139. Latin America IgA Nephropathy Drugs Sales Market Share by Country (2021-2026) Table 140. Latin America IgA Nephropathy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 141. Latin America IgA Nephropathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 142. Latin America IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Latin America IgA Nephropathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 144. Latin America IgA Nephropathy Drugs Market Share by Country (2021-2026) Table 145. Latin America IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Latin America IgA Nephropathy Drugs Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa IgA Nephropathy Drugs Sales by Country (2021-2026) & (K Units) Table 149. Middle East and Africa IgA Nephropathy Drugs Sales Market Share by Country (2021-2026) Table 150. Middle East and Africa IgA Nephropathy Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 151. Middle East and Africa IgA Nephropathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa IgA Nephropathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 154. Middle East and Africa IgA Nephropathy Drugs Market Share by Country (2021-2026) Table 155. Middle East and Africa IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Middle East and Africa IgA Nephropathy Drugs Market Share Forecast by Country (2027-2032) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. IgA Nephropathy Drugs Distributors List Table 160. IgA Nephropathy Drugs Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. IgA Nephropathy Drugs Image Figure 2. Global IgA Nephropathy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IgA Nephropathy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global IgA Nephropathy Drugs Sales (2021-2032) & (K Units) Figure 5. Phase I Image Figure 6. Global Phase I Sales YoY Growth (2021-2032) & (K Units) Figure 7. Phase II Image Figure 8. Global Phase II Sales YoY Growth (2021-2032) & (K Units) Figure 9. Phase III Image Figure 10. Global Phase III Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global IgA Nephropathy Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global IgA Nephropathy Drugs Market Share by Type 2025 VS 2032 Figure 13. North America IgA Nephropathy Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America IgA Nephropathy Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe IgA Nephropathy Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe IgA Nephropathy Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific IgA Nephropathy Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific IgA Nephropathy Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America IgA Nephropathy Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America IgA Nephropathy Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa IgA Nephropathy Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa IgA Nephropathy Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 IgA Nephropathy Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Clinical Treatment Image Figure 26. Global Clinical Treatment Sales YoY Growth (2021-2032) & (K Units) Figure 27. Drug Experiment Image Figure 28. Global Drug Experiment Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global IgA Nephropathy Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global IgA Nephropathy Drugs Market Share by Application 2025 VS 2032 Figure 31. North America IgA Nephropathy Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America IgA Nephropathy Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe IgA Nephropathy Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe IgA Nephropathy Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific IgA Nephropathy Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific IgA Nephropathy Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America IgA Nephropathy Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America IgA Nephropathy Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa IgA Nephropathy Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa IgA Nephropathy Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America IgA Nephropathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America IgA Nephropathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America IgA Nephropathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe IgA Nephropathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe IgA Nephropathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe IgA Nephropathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific IgA Nephropathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific IgA Nephropathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific IgA Nephropathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America IgA Nephropathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America IgA Nephropathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America IgA Nephropathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa IgA Nephropathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa IgA Nephropathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa IgA Nephropathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa IgA Nephropathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. IgA Nephropathy Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. IgA Nephropathy Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Phase I
  • Phase II
  • Phase III
Applications
  • Clinical Treatment
  • Drug Experiment
Companies covered
  • Calliditas Therapeutics
  • Chinook Therapeutics
  • Omeros Corporation
  • Travere Therapeutics
  • Vera Therapeutics
  • Otsuka Pharmaceutical
  • Novartis International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IgA Nephropathy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global IgA Nephropathy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 IgA Nephropathy Drugs Market by Type
  6. 1.3.1 Phase I
  7. 1.3.2 Phase II
  8. 1.3.3 Phase III
  9. 1.4 Global IgA Nephropathy Drugs Market Size by Type
  10. 1.4.1 Global IgA Nephropathy Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global IgA Nephropathy Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global IgA Nephropathy Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America IgA Nephropathy Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe IgA Nephropathy Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific IgA Nephropathy Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America IgA Nephropathy Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa IgA Nephropathy Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 IgA Nephropathy Drugs Industry Trends
  2. 2.2 IgA Nephropathy Drugs Industry Drivers
  3. 2.3 IgA Nephropathy Drugs Industry Opportunities and Challenges
  4. 2.4 IgA Nephropathy Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by IgA Nephropathy Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by IgA Nephropathy Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by IgA Nephropathy Drugs Price (2021-2026)
  4. 3.4 Global IgA Nephropathy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IgA Nephropathy Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global IgA Nephropathy Drugs Company, Product Type & Application
  7. 3.7 Global IgA Nephropathy Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IgA Nephropathy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IgA Nephropathy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IgA Nephropathy Drugs Tier 1, Tier 2, and Tier 3
4 IgA Nephropathy Drugs Regional Status and Outlook
  1. 4.1 Global IgA Nephropathy Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global IgA Nephropathy Drugs Historic Market Size by Region
  3. 4.2.1 Global IgA Nephropathy Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global IgA Nephropathy Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global IgA Nephropathy Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global IgA Nephropathy Drugs Forecasted Market Size by Region
  7. 4.3.1 Global IgA Nephropathy Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global IgA Nephropathy Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global IgA Nephropathy Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 IgA Nephropathy Drugs by Application
  1. 5.1 IgA Nephropathy Drugs Market by Application
  2. 5.1.1 Clinical Treatment
  3. 5.1.2 Drug Experiment
  4. 5.2 Global IgA Nephropathy Drugs Market Size by Application
  5. 5.2.1 Global IgA Nephropathy Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global IgA Nephropathy Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global IgA Nephropathy Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America IgA Nephropathy Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe IgA Nephropathy Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific IgA Nephropathy Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America IgA Nephropathy Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa IgA Nephropathy Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Calliditas Therapeutics
  2. 6.1.1 Calliditas Therapeutics Company Information
  3. 6.1.2 Calliditas Therapeutics Business Overview
  4. 6.1.3 Calliditas Therapeutics IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Calliditas Therapeutics IgA Nephropathy Drugs Product Portfolio
  6. 6.1.5 Calliditas Therapeutics Recent Developments
  7. 6.2 Chinook Therapeutics
  8. 6.2.1 Chinook Therapeutics Company Information
  9. 6.2.2 Chinook Therapeutics Business Overview
  10. 6.2.3 Chinook Therapeutics IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Chinook Therapeutics IgA Nephropathy Drugs Product Portfolio
  12. 6.2.5 Chinook Therapeutics Recent Developments
  13. 6.3 Omeros Corporation
  14. 6.3.1 Omeros Corporation Company Information
  15. 6.3.2 Omeros Corporation Business Overview
  16. 6.3.3 Omeros Corporation IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Omeros Corporation IgA Nephropathy Drugs Product Portfolio
  18. 6.3.5 Omeros Corporation Recent Developments
  19. 6.4 Travere Therapeutics
  20. 6.4.1 Travere Therapeutics Company Information
  21. 6.4.2 Travere Therapeutics Business Overview
  22. 6.4.3 Travere Therapeutics IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Travere Therapeutics IgA Nephropathy Drugs Product Portfolio
  24. 6.4.5 Travere Therapeutics Recent Developments
  25. 6.5 Vera Therapeutics
  26. 6.5.1 Vera Therapeutics Company Information
  27. 6.5.2 Vera Therapeutics Business Overview
  28. 6.5.3 Vera Therapeutics IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Vera Therapeutics IgA Nephropathy Drugs Product Portfolio
  30. 6.5.5 Vera Therapeutics Recent Developments
  31. 6.6 Otsuka Pharmaceutical
  32. 6.6.1 Otsuka Pharmaceutical Company Information
  33. 6.6.2 Otsuka Pharmaceutical Business Overview
  34. 6.6.3 Otsuka Pharmaceutical IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Otsuka Pharmaceutical IgA Nephropathy Drugs Product Portfolio
  36. 6.6.5 Otsuka Pharmaceutical Recent Developments
  37. 6.7 Novartis International
  38. 6.7.1 Novartis International Company Information
  39. 6.7.2 Novartis International Business Overview
  40. 6.7.3 Novartis International IgA Nephropathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Novartis International IgA Nephropathy Drugs Product Portfolio
  42. 6.7.5 Novartis International Recent Developments
7 North America by Country
  1. 7.1 North America IgA Nephropathy Drugs Sales by Country
  2. 7.1.1 North America IgA Nephropathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America IgA Nephropathy Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America IgA Nephropathy Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America IgA Nephropathy Drugs Market Size by Country
  6. 7.2.1 North America IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America IgA Nephropathy Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe IgA Nephropathy Drugs Sales by Country
  2. 8.1.1 Europe IgA Nephropathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe IgA Nephropathy Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe IgA Nephropathy Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe IgA Nephropathy Drugs Market Size by Country
  6. 8.2.1 Europe IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe IgA Nephropathy Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific IgA Nephropathy Drugs Sales by Country
  2. 9.1.1 Asia-Pacific IgA Nephropathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific IgA Nephropathy Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific IgA Nephropathy Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific IgA Nephropathy Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific IgA Nephropathy Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America IgA Nephropathy Drugs Sales by Country
  2. 10.1.1 South America IgA Nephropathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America IgA Nephropathy Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America IgA Nephropathy Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America IgA Nephropathy Drugs Market Size by Country
  6. 10.2.1 South America IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America IgA Nephropathy Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa IgA Nephropathy Drugs Sales by Country
  2. 11.1.1 Middle East and Africa IgA Nephropathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa IgA Nephropathy Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa IgA Nephropathy Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa IgA Nephropathy Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa IgA Nephropathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa IgA Nephropathy Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa IgA Nephropathy Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 IgA Nephropathy Drugs Value Chain Analysis
  2. 12.1.1 IgA Nephropathy Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 IgA Nephropathy Drugs Production Mode & Process
  7. 12.2 IgA Nephropathy Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 IgA Nephropathy Drugs Distributors
  10. 12.2.3 IgA Nephropathy Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst